FrancophonIA/ELRC3.0 huggingface dataset:
English: Revinty Ellipta contains the active substances fluticasone furoate and vilanterol.
Slovenian: Zdravilo Revinty Ellipta vsebuje učinkovini flutikazonfuroat in vilanterol.
English: For the full list of side effects of Revinty Ellipta, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov, o katerih so poročali pri uporabi zdravila Revinty Ellipta, glejte navodilo za uporabo.
English: How is Revinty Ellipta used?
Slovenian: Kako se zdravilo Revinty Ellipta uporablja?
English: • whose symptoms are adequately controlled with both inhaled corticosteroids and a long-acting
Slovenian: • katerih simptomi so ustrezno obvladani z inhalacijskimi kortikosteroidi in dolgodelujočim agonistom adrenergičnih receptorjev beta2.
English: How does Revinty Ellipta work?
Slovenian: Kako zdravilo Revinty Ellipta deluje?
English: Revinty Ellipta can only be obtained with a prescription.
Slovenian: Predpisovanje in izdaja zdravila je le na recept.
English: Patients need to receive an initial higher dose (loading dose) on the first day.
Slovenian: Bolniki morajo prvi dan prejeti večji začetni odmerek (polnilni odmerek).
English: The aim of the loading dose is to attain effective blood levels quickly.
Slovenian: Namen polnilnega odmerka je hitro doseči učinkovite ravni zdravila v krvi.
English: The dose may be increased or decreased according to how the patient responds.
Slovenian: Odmerek je glede na odziv bolnika mogoče povečati ali zmanjšati.
English: Without ergosterol, the fungus cannot spread or dies.
Slovenian: Brez ergosterola se glivice ne morejo razmnoževati in posledično odmrejo.
English: As for every medicine, the company provided studies on the quality of voriconazole.
Slovenian: Kot to velja za vsako zdravilo, je družba zagotovila študije o kakovosti vorikonazola.
English: The full EPAR and risk management plan summary for Voriconazole Hikma can be found on the Agency's website: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
Slovenian: Celotno evropsko javno poročilo o oceni zdravila (EPAR) in povzetek načrta obvladovanja tveganj za zdravilo Vorikonazol Hikma sta na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Human medicines/European public assessment reports.
English: It works by disrupting the formation of ergosterol, which is an important part of fungal cell membranes.
Slovenian: Deluje tako, da preprečuje tvorbo ergosterola, ki je pomembna sestavina celičnih membran glivic.
English: The loading dose is then followed by a maintenance dose that can be adjusted according to the patient's response.
Slovenian: Polnilnemu odmerku sledi vzdrževalni odmerek, ki ga je mogoče prilagoditi glede na odziv bolnika.
English: The Agency's Committee for Medicinal Products for Human Use (CHMP) concluded that, in accordance with EU requirements, Voriconazole Hikma has been shown to be comparable to Vfend.
Slovenian: Odbor za zdravila za uporabo v humani medicini (CHMP) pri agenciji je zaključil, da je bilo v skladu z zahtevami EU dokazano, da je zdravilo Vorikonazol Hikma primerljivo z zdravilom Vfend.
English: The European Commission granted a marketing authorisation valid throughout the European Union for Voriconazole Hikma on 27 May 2015.
Slovenian: Evropska komisija je dovoljenje za promet z zdravilom Vorikonazol Hikma, veljavno po vsej Evropski uniji, izdala 27. maja 2015.
English: This is a summary of the European public assessment report (EPAR) for Voriconazole Hikma.
Slovenian: To je povzetek evropskega javnega poročila o oceni zdravila (EPAR) za zdravilo Vorikonazol Hikma.
English: Because Voriconazole Hikma is a generic medicine, its benefits and risks are taken as being the same as the reference medicine's.
Slovenian: Ker je zdravilo Vorikonazol Hikma generično zdravilo, so koristi in tveganja enaki kot pri referenčnem zdravilu.
English: • serious fungal infections caused by Scedosporium or Fusarium (two different types of fungus).
Slovenian: • resnih glivičnih okužb, ki jih povzročata Scedosporium in Fusarium (dve različni vrsti glivic).
English: Voriconazole Hikma is also used to prevent fungal infections in patients who have had haematopoietic (blood) stem-cell transplantation (a transplant of a type of stem cells that can develop into blood cells) and are at high risk of infection.
Slovenian: Zdravilo Vorikonazol Hikma se uporablja tudi za preprečevanje glivičnih okužb pri bolnikih, pri katerih so opravili presaditev matičnih (krvnih) celic (presaditev vrste matičnih celic, ki se lahko razvijejo v krvne celice) in pri katerih obstaja visoko tveganje za okužbe.
English: The Committee recommended that Voriconazole Hikma be approved for use in the EU.
Slovenian: Priporočil je, da se zdravilo Vorikonazol Hikma odobri za uporabo v EU.
English: • invasive aspergillosis (a type of fungal infection due to Aspergillus);
Slovenian: • invazivne aspergiloze (vrste glivične okužbe, ki jo povzroča glivica Aspergillus);
English: There was no need for ‘bioequivalence' studies to investigate whether voriconazole is absorbed similarly to the reference medicine, Vfend, to produce the same level of the active substance in the blood.
Slovenian: Izvedba študij biološke enakovrednosti, s katerimi se proučuje, ali se vorikonazol absorbira podobno kot referenčno zdravilo Vfend in tako ustvari enake ravni zdravilne učinkovine v krvi, ni bila potrebna.
English: Voriconazole Hikma is an antifungal medicine used for the treatment of adults and children over the age of two years who have the following infections caused by a fungus:
Slovenian: Vorikonazol Hikma je zdravilo proti glivicam, ki se uporablja pri odraslih in otrocih, starejših od dveh let, za zdravljenje naslednjih okužb, ki jih povzročajo glivice:
English: What measures are being taken to ensure the safe and effective use of Voriconazole Hikma?
Slovenian: Kateri ukrepi se izvajajo za zagotovitev varne in učinkovite uporabe zdravila Vorikonazol Hikma?
English: A risk management plan has been developed to ensure that Voriconazole Hikma is used as safely as possible.
Slovenian: Za zagotovitev čim varnejše uporabe zdravila Vorikonazol Hikma je bil pripravljen načrt obvladovanja tveganj.
English: This is because voriconazole is given by infusion into a vein, so the active substance is delivered straight into the bloodstream.
Slovenian: Razlog za to je dejstvo, da se vorikonazol daje z infundiranjem v veno, zaradi česar zdravilna učinkovina vstopi neposredno v krvni obtok.
English: Both the loading and the maintenance doses are given by infusion, but once patients improve prescribers should consider switching patients to a voriconazole medicine that can be given by mouth.
Slovenian: Polnilni in vzdrževalni odmerek se dajeta z infundiranjem, ko pa se stanje bolniku izboljša, naj zdravniki, ki predpisujejo zdravilo, premislijo o prehodu na zdravilo, ki vsebuje vorikonazol in se daje peroralno.
English: Based on this plan, safety information has been included in the summary of product characteristics and the package leaflet for Voriconazole Hikma, including the appropriate precautions to be followed by healthcare professionals and patients.
Slovenian: V skladu s tem načrtom so bile v povzetek glavnih značilnosti zdravila Vorikonazol Hikma in navodilo za njegovo uporabo vključene informacije o varnosti, vključno s previdnostnimi ukrepi, ki jih morajo upoštevati zdravstveni delavci in bolniki.
English: • candidaemia (a type of fungal infection due to Candida) in patients with a normal white blood cell count;
Slovenian: • kandidemije (druge vrste glivične okužbe, ki jo povzroča glivica Candida) pri bolnikih z normalnimi ravnmi belih krvnih celic;
English: When used for treating fungal infections, Voriconazole Hikma is intended mainly for patients with infections that are worsening and possibly life-threatening.
Slovenian: Kadar se zdravilo Vorikonazol Hikma uporablja za zdravljenje glivičnih okužb, je namenjeno predvsem bolnikom, pri katerih se okužba poslabšuje in je potencialno smrtno nevarna.
English: For more information about treatment with Voriconazole Hikma, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.
Slovenian: Za več informacij o zdravljenju z zdravilom Vorikonazol Hikma preberite navodilo za uporabo (ki je prav tako del EPAR) ali se posvetujte z zdravnikom ali farmacevtom.
English: Therefore, the CHMP's view was that, as for Vfend, the benefit outweighs the identified risk.
Slovenian: Zato je menil, da njegove koristi enako kot pri zdravilu Vfend odtehtajo znana tveganja.
English: Voriconazole Hikma voriconazole
Slovenian: Vorikonazol Hikma vorikonazol
English: For practical information about using Voriconazole Hikma, patients should read the package leaflet or contact their doctor or pharmacist.
Slovenian: Za praktične informacije o uporabi zdravila Vorikonazol Hikma naj bolniki preberejo navodilo za uporabo ali se posvetujejo z zdravnikom ali farmacevtom.
English: • other serious invasive Candida infections when the fungus is resistant to fluconazole (another antifungal medicine);
Slovenian: • drugih resnih invazivnih okužb, ki jih povzroča glivica Candida, ki je odporna proti flukonazolu (drugemu zdravilu proti glivicam);
English: What are the benefits and risks of Voriconazole Hikma?
Slovenian: Kakšne so koristi in tveganja, povezani z zdravilom Vorikonazol Hikma?
English: The list of fungi against which Voriconazole Hikma is active can be found in the summary of product characteristics (also part of the EPAR).
Slovenian: Za seznam glivic, proti katerim deluje zdravilo Vorikonazol Hikma, glejte povzetek glavnih značilnosti zdravila (ki je prav tako del EPAR).
English: What is Voriconazole Hikma and what is it used for?
Slovenian: Kaj je zdravilo Vorikonazol Hikma in za kaj se uporablja?
English: Voriconazole Hikma is available as a powder to be made up into a solution for infusion (drip) into a vein.
Slovenian: Zdravilo Vorikonazol Hikma je na voljo v obliki praška za pripravo raztopine za infundiranje (kapalne infuzije) v veno.
English: Other information about Voriconazole Hikma
Slovenian: Druge informacije o zdravilu Vorikonazol Hikma
English: This means that Voriconazole Hikma is similar to a ‘reference medicine' already authorised in the European Union
Slovenian: To pomeni, da je podobno „referenčnemu zdravilu“, ki je že odobreno v Evropski uniji (EU), in sicer zdravilu Vfend.
English: The active substance in Voriconazole Hikma, voriconazole, belongs to the ‘triazole' class of antifungal medicines.
Slovenian: Zdravilna učinkovina v zdravilu Vorikonazol Hikma, vorikonazol, spada v skupino zdravil proti glivičnim okužbam, ki jih imenujemo „triazoli“.
English: Why is Voriconazole Hikma approved?
Slovenian: Zakaj je bilo zdravilo Vorikonazol Hikma odobreno?
English: The dose of Voriconazole Hikma depends on the weight of the patient.
Slovenian: Daje se dvakrat na dan. Odmerek zdravila Vorikonazol Hikma, ki ga je treba dati, je odvisen od telesne mase bolnika.
English: How is Voriconazole Hikma used?
Slovenian: Kako se zdravilo Vorikonazol Hikma uporablja?
English: Voriconazole Hikma contains the active substance voriconazole.
Slovenian: Zdravilo Vorikonazol Hikma vsebuje zdravilno učinkovino vorikonazol.
English: How has Voriconazole Hikma been studied?
Slovenian: Kako je bilo zdravilo Vorikonazol Hikma raziskano?
English: How does Voriconazole Hikma work?
Slovenian: Kako zdravilo Vorikonazol Hikma deluje?
English: It is not intended to provide practical advice on how to use Voriconazole Hikma.
Slovenian: Povzetek ni namenjen zagotavljanju praktičnih nasvetov o njegovi uporabi.
English: Risk Management Plan(RMP)
Slovenian: • Načrt za obvladovanje tveganja (RMP)
English: • Your doctor may order blood tests.
Slovenian: • lahko vaš zdravnik naroči preiskave krvi
English: Combined therapy should be started as early as possible after symptoms start and continued for at least four weeks.
Slovenian: S kombiniranim zdravljenjem je treba začeti čim prej po nastopu simptomov in z njim nadaljevati vsaj štiri tedne.
English: EU/1/09/568/001 Cartons of 7 film-coated tablets in PVC/PE/PVDC/Alu blisters EU/1/09/568/002 Cartons of 14 film-coated tablets in PVC/PE/PVDC/Alu blisters EU/1/09/568/003 Cartons of 28 film-coated tablets in PVC/PE/PVDC/Alu blisters EU/1/09/568/004 Cartons of 30 film-coated tablets in PVC/PE/PVDC/Alu blisters EU/1/09/568/005 Cartons of 50 film-coated tablets in PVC/PE/PVDC/Alu blisters EU/1/09/568/006 Cartons of 56 film-coated tablets in PVC/PE/PVDC/Alu blisters EU/1/09/568/007 Cartons of 84 film-coated tablets in PVC/PE/PVDC/Alu blisters EU/1/09/568/008 Cartons of 90 film-coated tablets in PVC/PE/PVDC/Alu blisters EU/1/09/568/009 Cartons of 100 film-coated tablets in PVC/PE/PVDC/Alu blisters EU/1/09/568/010 Cartons of 7 film-coated tablets in PA/ALL/PVDC/Alu blisters EU/1/09/568/011 Cartons of 14 film-coated tablets in PA/ALL/PVDC /Alu blisters EU/1/09/568/012 Cartons of 28 film-coated tablets in PA/ALL/PVDC /Alu blisters EU/1/09/568/013 Cartons of 30 film-coated tablets in PA/ALL/PVDC /Alu blisters EU/1/09/568/014 Cartons of 50 film-coated tablets in PA/ALL/PVDC /Alu blisters EU/1/09/568/015 Cartons of 56 film-coated tablets in PA/ALL/PVDC /Alu blisters EU/1/09/568/016 Cartons of 84 film-coated tablets in PA/ALL/PVDC /Alu blisters
Slovenian: EU/1/09/568/001-001 škatle s 7 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-002 škatle s 14 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-003 škatle z 28 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-004 škatle s 30 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-005 škatle s 50 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-006 škatle s 56 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-007 škatle s 84 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-008 škatle z 90 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-009 škatle s 100 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-010 škatle s 7 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-011 škatle s 14 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-012 škatle z 28 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-013 škatle s 30 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-014 škatle s 50 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-015 škatle s 56 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-016 škatle z 84 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih EU/1/09/568/001-017 škatle z 90 filmsko obloženimi tabletami v PVC/PVDC/alu pretisnih omotih
English: anti-retroviral medicines (medicines to treat HIV infections).
Slovenian: - protiretrovirusna zdravila (zdravila za zdravljenje okužbe z virusom HIV).
English: Date of first authorisation: 16.10.2009 Date of latest renewal: 18.09.2014
Slovenian: Datum zadnjega podaljšanja dovoljenja za promet: 18.09.2014
English: This leaflet was last revised in {MM/YYYY} .
Slovenian: Navodilo je bilo nazadnje revidirano {MM/LLLL}
English: An occasional use of acetylsalicylic acid (no more than 1,000 mg in any 24 hour period) should generally not cause a problem, but prolonged use in other circumstances should be discussed with your doctor.
Slovenian: Priložnostna uporaba acetilsalicilne kisline (ne več kot 1.000 mg v kateremkoli 24-urnem obdobju) na splošno ne bi smela povzročati težav, vendar pa se morate o daljši uporabi v drugih okoliščinah posvetovati s svojim zdravnikom.
English: ANNEX II A. MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE B. CONDITIONS OR RESTRICTION REGARDING SUPPLY AND USE C. OTHER CONDITIONS AND REQUIREMENTS OF THE MARKETING AUTHORISATION D. CONDITIONS OR RESTRICTIONS WITH REGARD TO THE SAFE AND EFFECTIVE USE OF THE MEDICINAL PRODUCT
Slovenian: PRILOGA II A. IZDELOVALEC (IZDELOVALCI), ODGOVORNI ZA SPROŠČANJE SERIJE B. POGOJI ALI OMEJITVE GLEDE OSKRBE IN UPORABE C. DRUGI POGOJI IN ZAHTEVE DOVOLJENJA ZA PROMET Z ZDRAVILOM D. POGOJI ALI OMEJITVE V ZVEZI Z VARNO IN UČINKOVITO UPORABO ZDRAVILA
English: 4.7 Effects on ability to drive and use machines Clopidogrel has no or negligible influence on the ability to drive and use machines.
Slovenian: 4.7 Vpliv na sposobnost vožnje in upravljanja s stroji Klopidogrel nima ali ima zanernarljiv vpliv na sposobnost za vožnjo in upravljanje strojev.
English: You have been prescribed Clopidogrel Apotex to help prevent blood clots and reduce the risk of these severe events because:
Slovenian: Zdravilo Clopidogrel Apotex vam je predpisani za pomoč pri preprečevanju nastajanja krvnih strdkov in za zmanjšanje tveganja teh hudih dogodkov, ker:
English: PHARMACEUTICAL FORM Film-coated tablet.
Slovenian: FARMACEVTSKA OBLIKA filmsko obložena tableta.
English: Their frequency is defined using the following conventions: common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000), not known (cannot be estimated from the available data).
Slovenian: Njihova pogostnost je navedena upoštevaje naslednji dogovor: pogosti (≥ 1/100, < 1/10), občasni (≥ 1/1.000, < 1/100), redki (≥ 1/10.000, < 1/1.000), zelo redki (< 1/10.000), neznana (ni mogoče oceniti iz razpoložljivih podatkov.
English: Excipients with a known effect:
Slovenian: Pomožne snovi z znanim učinkom:
English: Some other medicines may influence the use of Clopidogrel Apotex or vice versa.
Slovenian: Nekatera druga zdravila lahko vplivajo na uporabo zdravila Clopidogrel Apotex in obratno.
English: The results obtained in populations with different characteristics (e.g. unstable angina or non-Q-wave MI, low to high risk levels, diabetes, need for revascularisation, age, gender, etc.) were consistent with the results of the primary analysis.
Slovenian: Rezultati, pridobljeni pri populacijah z različnimi karakteristikami (npr. nestabilna angina, MI brez Qzobca, visoka do nizka raven tveganja, diabetes, potreba po revaskularizaciji, spol, starost, itd), so skladni z rezultati primarne analize.
English: Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other concomitant medicinal products to investigate the potential for pharmacodynamic and pharmacokinetic interactions.
Slovenian: Druga zdravila: Številne druge klinične študije so izvedli s klopidogrelom in drugimi sočasno danimi zdravili, da bi proučili potencial za farmakodinamične in farmakokinetične interakcije.
English: You should take Clopidogrel Apotex for as long as your doctor continues to prescribe it.
Slovenian: Zdravilo Clopidogrel Apotex morate jemati, vse dokler vam ga vaš zdravnik predpisuje.
English: In addition, a subgroup analysis by age suggested that the benefit of clopidogrel in patients over 75 years was less than that observed in patients 75 years.
Slovenian: Razen tega analiza podskupin glede na starost nakazuje, da so koristi klopidogrela pri bolnikih, starejših od 75 let, manjše od tistih, ki so jih opazili pri bolnikih ≤ 75 let.
English: Marketing Authorisation Holder and Manufacturers:
Slovenian: Imetnik dovoljenja za promet z zdravilom in izdelovalci:
English: • Paediatric population Clopidogrel should not be used in children because of efficacy concerns (see section 5.1).
Slovenian: • Pediatrična populacija Klopidogrel naj se pri otrocih ne uporablja iz razlogov, ki zadevajo učinkovitost (glejte poglavje 5.1.
English: Contact your doctor immediately if you experience: - fever, signs of infection or extreme tiredness.
Slovenian: Nemudoma se posvetujte s svojim zdravnikom, če se pri vas pojavijo: zvišana telesna temperatura, znaki okužbe ali huda utrujenost.
English: Pregnancy and breast-feeding It is preferable not to take this medicine during pregnancy.
Slovenian: Nosečnost in dojenje Priporočljivo je, da se tega zdravila v nosečnosti ne uporablja.
English: Prevention of atherothrombotic and thromboembolic events in atrial fibrillation
Slovenian: Preprečevanje aterotrombotičnih in trombemboličnih dogodkov pri atrijski fibrilaciji
English: Clopidogrel Apotex with food and drink Clopidogrel Apotex may be taken with or without food.
Slovenian: Zdravilo Clopidogrel Apotex skupaj s hrano in pijačo Zdravilo Clopidogrel Apotex lahko jemljete s hrano ali brez nje.
English: Published frequencies for the poor CYP2C19 metaboliser genotypes are approximately 2% for Caucasians, 4% for Blacks and 14% for Chinese.
Slovenian: Objavljene pogostnosti genotipa slabega metabolizatorja s CYP2C19 so približno 2 % pri belcih, 4 % pri črncih in 14 % pri Kitajcih.
English: There have been a number of retrospective analyses, however, to evaluate this effect in patients treated with clopidogrel for whom there are genotyping results: CURE (n=2721), CHARISMA (n=2428), CLARITY-TIMI 28 (n=227), TRITON-TIMI 38 (n=1477), and ACTIVE-A (n=601), as well as a number of published cohort studies.
Slovenian: Opravljene pa so bile številne retrospektivne analize za oceno tega učinka pri bolnikih, zdravljenih s klopidogrelom, za katere so na voljo rezultati genotipizacije: CURE (n = 2721), CHARISMA (n = 2428), CLARITY-TIMI 28 (n = 227), TRITONTIMI 38 (n = 1477) in ACTIVE-A (n = 601), poleg tega pa tudi številne objavljene kohortne študije.
English: Bleeding time prolonged, neutrophil count decreased, platelet count decreased * Information related to clopidogrel with frequency “not known”.
Slovenian: Podaljšan čas krvavitve, zmanjšano število nevtrofilcev, zmanjšano število trombocitov * Podatki se nanašajo na klopidogrel s pogostnostjo “ neznani”.
English: Analysis of total mortality as a secondary endpoint did not show any significant difference between clopidogrel (5.8%) and ASA (6.0%).
Slovenian: Analiza skupne umrljivosti kot sekundarnega opazovanega dogodka ni pokazala pomembne razlike med klopidogrelom (5,8 %) in ASA
English: Warnings and precautions If any of the situations mentioned below apply to you, you should tell your doctor before taking Clopidogrel Apotex:
Slovenian: Opozorila in previdnostni ukrepi Če katero koli od spodaj navedenih stanj velja za vas, morate o tem obvestiti svojega zdravnika, preden boste vzeli zdravilo Clopidogrel Apotex:
English: Blisters of white PVC/PE/PVDC-aluminium foil or PA/ALL/PVC-aluminium foil.
Slovenian: Pretisni omoti iz bele PVC/PE/PVDC-aluminijaste folije ali PA/ALL/PVC-aluminijaste folije.
English: Pharmacotherapeutic group: platelet aggregation inhibitors excl. heparin, ATC Code: B01AC-04.
Slovenian: Farmakoterapevtska skupina: zaviralci agregacije trombocitov brez heparina, oznaka ATC: B01AC-04.
English: You should have been told that ‘oral anticoagulants' are more effective than acetylsalicylic acid or the combined use of Clopidogrel and acetylsalicylic acid for this condition.
Slovenian: Povedati so vam morali, da so "peroralni antikoagulanti" pri tej motnji učinkovitejši kot acetilsalicilna kislina ali kombinirana uporaba zdravila Clopidogrel Apotex in acetilsalicilne kisline.
English: Then, the recommended dose is one 75-mg tablet of Clopidogrel Apotex per day as described above.
Slovenian: Nato je priporočeni odmerek ena 75-mg tableta zdravila Clopidogrel Apotex na dan, kot je opisano zgoraj.
English: The recommended dose, including for patients with a condition called ‘atrial fibrillation' (an irregular heartbeat), is one 75 mg tablet of Clopidegrel Apotex per day to be taken orally with or without food, and at the same time each day.
Slovenian: Priporočeni odmerek, vključno za bolnike s stanjem, imenovanim "atrijska fibrilacija" (neredno bitje srca), je ena 75-mg tableta zdravila Clopidegrel Apotex na dan, ki se jemlje peroralno s hrano ali brez nje, vsak dan ob istem času.
English: Pharmathen S.A., 6 Dervenakion 15351 Pallini Attiki Greece
Slovenian: Pharmathen S.A., 6 Dervenakion 15351 Pallini Attiki Grčija
English: The clinically relevant adverse reactions observed in the CAPRIE, CURE, CLARITY, COMMIT and ACTIVE-A studies are discussed below.
Slovenian: Klinično pomembni neželeni učinki, zabeleženi v študijah CAPRIE, CURE, CLARITY, COMMIT in ACTIVE-A so predstavljeni spodaj.